Login to Your Account



Pharma: Clinic Roundup


Friday, June 14, 2013

• Janssen Research & Development LLC, of Spring House, Pa., a unit of Johnson & Johnson, said a Phase III study published in The Lancet showed patients with active psoriatic arthritis who received either Stelara (ustekinumab) 45 mg or 90 mg achieved significant improvement in joint symptoms at the study's primary endpoint, compared to patients receiving placebo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription